• Register
  • Login

European Journal of Molecular & Clinical Medicine

  • Home
  • Browse
    • Current Issue
    • By Issue
    • By Subject
    • Keyword Index
    • Author Index
    • Indexing Databases XML
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Indexing and Abstracting
    • Peer Review Process
    • News
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
Advanced Search

Notice

As part of Open Journals’ initiatives, we create website for scholarly open access journals. If you are responsible for this journal and would like to know more about how to use the editorial system, please visit our website at https://ejournalplus.com or
send us an email to info@ejournalplus.com

We will contact you soon

  1. Home
  2. Volume 9, Issue 7
  3. Author

Online ISSN: 2515-8260

Volume9, Issue7

CURRENT SCENARIO AND FUTURE ORCHESTRATIONS IN THE BATTLE AGAINST DYSLIPIDEMIA: REVIEW ON NOVEL HYPOLIPIDEMIC DRUGS

    Dr. Shoebul Haque, Dr. Ajit Mishra, Dr. Narendra Kumar Dr. Shakita Fatima, Prof. Amod Kumar Sachan Prof. Rakesh Kumar Dixit

European Journal of Molecular & Clinical Medicine, 2022, Volume 9, Issue 7, Pages 162-184

  • Show Article
  • Download
  • Cite
  • Statistics
  • Share

Abstract

Cholesterol is an essential constituent of the cell membrane. It coordinates carbohydrate, major ions, and bone homeostasis respectively. [1] Cholesterol is the progenitor for all glucocorticoids, mineralocorticoids, sex hormones, steroids, and cholecalciferol. Cholesterol is transported into the blood via spherical macromolecules like chylomicrons, HDL, LDL, and VLDL. [2] These properties make it an essential biomolecule for most physiological mechanisms. Triglycerides performing a key role in providing energy to cells. [3] In excess amounts, these biomolecules are not good for health and produce hyperlipidemia. [4] Hyperlipidemia is responsible for many long-term side effects in the body. Hyperlipidemia increases the risk of formation of plaques, which promotes the risk of heart attack and stroke in persons with atherosclerosis and coronary heart diseases. [5] Statins are the evidence-based treatment option for hyperlipidemia according to published guidelines. 
Keywords:
  • PDF (687 K)
  • XML
(2022). CURRENT SCENARIO AND FUTURE ORCHESTRATIONS IN THE BATTLE AGAINST DYSLIPIDEMIA: REVIEW ON NOVEL HYPOLIPIDEMIC DRUGS. European Journal of Molecular & Clinical Medicine, 9(7), 162-184.
Dr. Shoebul Haque, Dr. Ajit Mishra, Dr. Narendra Kumar Dr. Shakita Fatima, Prof. Amod Kumar Sachan Prof. Rakesh Kumar Dixit. "CURRENT SCENARIO AND FUTURE ORCHESTRATIONS IN THE BATTLE AGAINST DYSLIPIDEMIA: REVIEW ON NOVEL HYPOLIPIDEMIC DRUGS". European Journal of Molecular & Clinical Medicine, 9, 7, 2022, 162-184.
(2022). 'CURRENT SCENARIO AND FUTURE ORCHESTRATIONS IN THE BATTLE AGAINST DYSLIPIDEMIA: REVIEW ON NOVEL HYPOLIPIDEMIC DRUGS', European Journal of Molecular & Clinical Medicine, 9(7), pp. 162-184.
CURRENT SCENARIO AND FUTURE ORCHESTRATIONS IN THE BATTLE AGAINST DYSLIPIDEMIA: REVIEW ON NOVEL HYPOLIPIDEMIC DRUGS. European Journal of Molecular & Clinical Medicine, 2022; 9(7): 162-184.
  • RIS
  • EndNote
  • BibTeX
  • APA
  • MLA
  • Harvard
  • Vancouver
  • Article View: 112
  • PDF Download: 99
  • LinkedIn
  • Twitter
  • Facebook
  • Google
  • Telegram
Journal Information

Publisher:

Email:  editor.ejmcm21@gmail.com

  • Home
  • Glossary
  • News
  • Aims and Scope
  • Privacy Policy
  • Sitemap

 

For Special Issue Proposal : editor.ejmcm21@gmail.com

This journal is licensed under a Creative Commons Attribution 4.0 International (CC-BY 4.0)

Powered by eJournalPlus